CRISPR, Vertex say FDA granted rolling review to experimental CRISPR therapy
Yahoo! Finance
CRISPR Therapeutics Inc. and Vertex Pharmaceuticals Inc. said Tuesday that the Food and Drug Administration granted a rolling review to the exagamglogene autotemcel, the therapy the companies are developing to treat sickle cell disease and transfusion-dependent beta thalassemia. CRISPR's stock was up 3.1% in premarket trading on Tuesday, while Vertex shares gained 1.1%. Vertex said it plans to a submit an application to the FDA in November, with plans to complete the submission in the first quar
Continue Reading